<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The authors report the case of a 18 year old man with a <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:chebi fb="0" ids="50858">corticosteroid</z:chebi>-refractory <z:hpo ids='HP_0000100'>nephrotic syndrome</z:hpo> complicated by carotid artery <z:mp ids='MP_0005048'>thrombosis</z:mp> and <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0001907'>Thromboembolism</z:hpo> is one of the most serious complications of the <z:hpo ids='HP_0000100'>nephrotic syndrome</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Serious clotting factor disturbances are observed: changes in platelet function (hyperaggregability) increased plasma zymogens and cofactors, increased plasma fibrinogen, abnormalities of the fibrinolytic system and acquired deficiencies of coagulation inhibitors </plain></SENT>
<SENT sid="3" pm="."><plain>The respective role of each of these abnormalities have not been clearly established, but it is likely that <z:mp ids='MP_0009586'>increased platelet aggregation</z:mp> and <z:hpo ids='HP_0001976'>antithrombin III deficiency</z:hpo> are important factors in producing a <z:e sem="disease" ids="C0398623" disease_type="Disease or Syndrome" abbrv="">hypercoagulable state</z:e> in the <z:hpo ids='HP_0000100'>nephrotic syndrome</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0003077'>Hyperlipidemia</z:hpo> is also a characteristic feature of the <z:hpo ids='HP_0000100'>nephrotic syndrome</z:hpo>: these is a wide spectrum of <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> patterns with increased <z:chebi fb="2" ids="39026">low density lipoproteins</z:chebi> (<z:chebi fb="15" ids="39026">LDL</z:chebi>) or <z:chebi fb="0" ids="39027">very low density lipoproteins</z:chebi> (<z:chebi fb="1" ids="39027">VLDL</z:chebi>) or both; contradictory results have been reported with respect to the <z:chebi fb="6" ids="39025">high density lipoproteins</z:chebi> (<z:chebi fb="17" ids="39025">HDL</z:chebi>): decreased, <z:mpath ids='MPATH_458'>normal</z:mpath> or even increased plasma levels have been observed </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, changes in the distribution and composition of <z:chebi fb="15" ids="39026">LDL</z:chebi> and <z:chebi fb="1" ids="39027">VLDL</z:chebi> subclasses have been detected </plain></SENT>
<SENT sid="6" pm="."><plain>Most of these changes have an atherogenic potential but controversy still surrounds the question of the prevalence of <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischaemic heart disease</z:e> in the <z:hpo ids='HP_0000100'>nephrotic syndrome</z:hpo>; it is unlikely that <z:hpo ids='HP_0000100'>nephrotic syndromes</z:hpo> of short duration have any influence on the incidence of coronary events, but patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> heavy protein <z:chebi fb="20" ids="16199">urea</z:chebi> and long-term exposure to abnormalities of haemostasis and <z:chebi fb="23" ids="18059">lipid</z:chebi> profiles appear to have a significant risk of developing <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> and may require long-term <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy </plain></SENT>
</text></document>